CKD represents the ninth most common cause of death in the United States but, despite this
large health burden, treatment options for affected patients remain limited. To remedy this,
several relevant pathways have been identified that may lead to novel therapeutic options.
Among them, altered renal lipid metabolism, first described in 1982, has been recognized as
a common pathway in clinical and experimental CKD of both metabolic and nonmetabolic
origin. This observation has led many researchers to investigate the cause of this renal …